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Table 1. Characteristics of Patients with New Allergic Symptoms after Cord Blood Transplantation
Variable lists Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age (gender) 54 (F) 41 (F) 39 (F) 3 (F) 43 (F)
Disease MDS CML/FCCL NK tcell lymphoma AML MDS/MPD
Pre-CBTallergy Codfish, celery, ginger None None None None
Conditioning regimen Flu/cy/tbi Flu/cy/tbi Flu/cy/tbi Cy/tbi/atg Flu/cy/tbi
CB cell dose 3.57 x 107 2.15 x 107 female 3.5x 107 3.86 x 107 5.02 x 107
GVHD prophylaxis FK and MMF FK and MMF FK and MMF FK and MMF FK and MMF
Acute GVHD + skin, + gut grade 2 + gut grade 2 + skin grade 3 None + gut grade 2
Chronic GVHD None + skin, gut , oral +gut and vaginal None None
Chimerism at the time
of new allergy
100% 100% 100% 100% 100%
New allergy documented
(days post- CBT)
+290 +250 +298 +809 +380
Impact on pre-CBT allergy Negative for previous allergies Na Na Na Na
Presenting sign and
symptoms
Vomiting with ingestion
of peanuts
Severe vomiting Throat closing swelling Painful itching blisters to
lips and mouth
Nausea/vomiting/diarrhea
Skin testing results + mites, cat, grass,
weed, tree, egg
white and yolk
+ grass, weeds, tress,
almond, walnut, brazil
nut, cashew, coconut
+ trees, grass, weeds, ragweed,
dust mites, dog, cat, peanut,
walnut, cashew, pecan, milk,
and egg
RAST 0.16kU/L (low) 5.88 kU/L (high)- almond;
and peanut 2.39 kU/L
(high)
Current IST None None None None None
Duration of follow-up (mo) 37 mo 39 mo 43 mo 46 mo 15mo
Current status Alive Alive Alive Alive Alive
CBT, cord blood transplantation; GVHD; Graft versus host disease.
*Result at the time of allergy evaluation; IST, immunosuppressive therapy; ALC, absolute lymphocyte count; mo, months; RAST, radioallergosorbent test.
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MAGNITUDE OF DYSLIPIDEMIAS AND CARDIOVASCULAR RISK IN SURVI-
VORS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
(SCT) UP TO THE SECOND DECADE POST-TRANSPLANT
Pophali, P.A.1, Klotz, J.1, Chawla, K.1, Koklanaris, E.1, Ito, S.1,
Le, R.Q.1, Savani, B.N.2, Barrett, J.1, Battiwalla, M.1 1NHLBI, NIH,
Bethesda, MD; 2Vanderbilt University, Nashville, TN
Introduction: Long term survivors of SCT have an increased risk of
cardiovascular disease which has not been well characterized.
Chronic GVHD (cGVHD) has been suspected to contribute to
this increased risk.
Methods: We evaluated the cardiovascular risk profiles in 109 sur-
vivors (62 males and 47 females) of SCT performed between 1993
and 2006. Median ages at transplant, 5 and 10 year post-SCT fol-
low-upwere 34, 40 and 46 years, respectively. Transplant indications
were CML (56), acute leukemia (29), MDS (13), and others (9).
Ninety-nine patients received $12 Gy TBI-based conditioning
and 10 patients received non-myeloablative conditioning followed
by marrow (15) or T cell depleted peripheral blood stem cell graft
(94). All females received hormone replacement therapy post-SCT.
Results:At the time of analysis, of 12 deaths, onewas due to a cardio-
vascular cause (stroke). Three survivors had non-fatal cardiovascular
events. There were significant increases in the prevalence of hyper-
tension (p# 0.001), diabetes (p5 0.018), elevatedC-reactive protein
(CRP) (p\0.001) and BodyMass Index (BMI) (p5 0.044) at follow-
up compared to baseline (Table). Survivors had higher rates of dys-
lipidemia meeting ATP III thresholds for drug therapy at 5 years
post-transplant (23%) compared to the general population (15%,
MESA study) (p\0.001). On calculating the Framingham general
cardiovascular risk score, the 10-year risk of developing a cardiovas-
cular event in male survivors at 5 years post-SCT nearly doubled
compared to normal (median 10.4% vs. 5.4%). The median calcu-
lated heart/vascular age was 8 years greater than the chronological
age for males. Females showed no increase in the cardiovascular
risk score. All risk factors stabilized between 5 and 10 years post-
SCT. cGVHD was not significantly associated with cardiovascular
risk factors at any time-point.
Conclusions: 1. Therapy requiring dyslipidemia in SCT survivors
occurs earlier and with a significantly greater frequency than in the
general population.2. At 5 years post transplant, male survivors have a doubling in the
10-year risk of developing a cardiovascular event and an 8-year in-
crease in heart/vascular age.
3. Although elevations in CRP suggest a persistent chronic inflam-
matory state, cGVHD does not impact cardiovascular risk.
Table.
Percentage increase in cardiovascular risk
factors from pre-transplant baseline at follow-up 5yrs (%) 10yrs (%)Diabetes 810 1005
Hypertension 292 563
Elevated BMI 14 58
CRP (as a continuous variable) 441 721223
PEDIATRIC REDUCED INTENSITY HEMATOPOIETIC PROGENITOR CELL
TRANSPLANTATION (HPCT) MAY CONFER LOWER RISK OF SECOND
MALIGNANT NEOPLASMS (SMNS)
Danner-Koptik, K.1, Narasimhan, S.3, Shah, N.4, Kletzel, M.1,2,
Hijiya, N.1,2, Dilley, K.J.1,2 1Children’s Memorial Hospital, Chicago,
IL; 2Feinberg School of Medicine, Northwestern University, Chicago,
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The occurrence of SMNs after HPCT is a potentially serious
problem for the pediatric population. Our initial intent was to com-
pare the incidence of SMNs in HPCT between traditional myeloa-
blative conditioning (TMC) and reduced intensity conditioning
(RIC) regimens, however, SMNs were only seen in the TMC group.
Conditioning regimen backbones were consistent within groups
with all allogeneic TMC SMNs having received total body irradia-
tion (TBI) 12 Gy, and RIC group with Fludarabine/Busulfan with-
out any radiation. Therefore, we compared the time at risk to
develop SMNs in the RIC group vs time to development in the
TMC group. Among pediatric patients who underwent HPCT in
our institution since 1992 and survived$ 3 years (n5 478; 166 allo-
geneic), 23 (5%) developed SMNs. Medical record review and
Poster Session I S287analysis of TMC and RIC cohorts from time of first HPCT showed
that all SMNs occurred in TMC patients who underwent HPCT for
malignancies, and 12/23 (52%) of SMNs were among allogeneic
HPCTs; 7% (12/166) SMNs developing in this total allogeneic co-
hort. Mean follow up for all TMCs in this group is 8.8 years and for
SMNs is 2.6 years from SMN onset (std. error 5 0.37) with overall
mortality of 26%.Mean time of SMN fromHPCTwas 15 years with
a range of 3.8–16 years. SMNs included thyroid papillary carcinoma
(8), MDS/AML (7), osteogenic sarcoma (3), chondrosarcoma (1),
gastrointestinal stromal tumor (GIST) (1), primitive neuroectoder-
mal tumor (PNET) (1), mucinous bile duct adenocarcinoma (1),
and Kaposi’s sarcoma (1). Comparing allogeneic TMC with SMN
to allogeneic RIC treated for malignancies, survival analysis censor-
ing for time at risk in RIC and time to SMN in TMC showed no sig-
nificant difference (log rank p5 .8364) with amean follow up for this
RIC group at 10.95 years and 15.03 years for the SMN in TMCs.
There was a difference between the same RIC group and autologous
HPCT with SMNs (n 5 11) in which 9/11 (82%) had HPCT for
NBL IV; despite no TBI for autologous HPCT these patients are
likely high risk for SMNs due to factors of prior exposure including
high doses of alkylating agents, topoisomerases, epidophyllotoxins,
and focal radiation. Although overall follow up time is relatively
short at a mean of 10 years, comparing time at risk among RIC pa-
tients to time to development of SMNs in TMC patients showed
no significant difference. This may support the hypothesis that de-
creasing or avoiding total body irradiation doses will lead to fewer
SMNs in survivors.224
A PROSPECTIVE COMPARISON OF SELF REPORTED QUALITY OF LIFE OF
CHILDREN AND THEIR PARENTS AFTER PEDIATRIC HEMATOPOIETIC
STEM-CELL TRANSPLANTATION
Armstrong, C.1, Pollock-BarZiv, S.M.2, Doyle, J.1, Egeler, M.1,
Gassas, A.1, Schechter, T.1 1The Hospital for Sick Children, Toronto,
ON, Canada; 2The Hospital for Sick Children, Toronto, ON, Canada
Background: Advances in hematopoeitic stem-cell transplantation
(HSCT) have significantly improved long-term survival and
HSCT is now the therapeutic treatment offered to patients with ma-
lignant and nonmalignant hematological diseases. The goal of
HSCT is to cure and enhance patient’s overall quality of life
(QOL); yet, QOL is multidimensional and rarely static. Further, lit-
tle research has compared parental and child perceptions of health
related quality of life. This study examined parental and child per-
ceivedQOLover the first year afterHSCT, exploring physical, emo-
tional, psychosocial, school function, and domains related to therapy
such as worry, nausea, and procedural and treatment anxiety.
Methods: Pediatric HSCT recipients and their parent each com-
pleted a questionnaire package at 3, 6, and 12 months post transplant
which included the Pediatric Quality of Life Inventory 4.0 (PedsQL
4.0) and the PedsQL Cancer Module. Scale scores for physical, psy-
chosocial, school domains were reported out of 100 where higher
scores reflect better functional status. Data were analyzed using de-
scriptive and univariate analyses with SAS software.
Results: There were 19 participants (68% male); 8 adolescents (age
13-18); 10 children ages 8-12; and 1 parent of a child ages 2-7. The
median age at HSCT was 11.5 yrs (range 2-17.2yrs).
Table. PedsQL 4.0 Mean (range) Core Scales for Children and
Parents, and Healthy Reference Scores and PedsQL Cancer
Module: Parent and Child Reports (Median Scores)
Mean
PedsQL 4.0 Parent Report Child Self-Report Reference*Physical Function Scale
3mo (n 5 19) 66 (16-97) 63 (38-97) 88.7
6 mo (n 5 14) 66 (59-100) 89 (47-97)
12 mo (n 5 9) 65 (25-100) 91 (53-100)
School Function Scale
3mo (n 5 19) 75 (35-100) 73 (0-90) 80.4
6 mo (n 5 14) 65 (45-100) 78 (50-100)(Continued )Table. (Continued)PedsQL 4.0 Parent Report Child Self-Report
Mean
Reference*12 mo (n 5 9) 75 (30-100) 80 (45-90)
Psychosocial Summary Score
3mo (n 5 19) 63 (38-93) 60 (0-93) 83.8
6 mo (n 5 14) 80 (25-98) 87 (40-98)
12 mo (n 5 9) 80 (37-100) 88 (38-97)
Cancer Module (median scores at 3m, 6m, 12m)
Pain and Hurt 81, 88, 63 75, 81, 81
Nausea 90, 90, 85 80, 90, 70
Procedural Anxiety 93, 75, 92 75, 75, 85
Treatment Anxiety 75, 83, 98 92, 92, 83
Worry 58.3, 75, 92 92, 85, 67
Physical Appearance 71, 83, 100 83, 88, 83Conclusions: These results suggest that parent and children report
discordant perceptions of QOL ratings after HSCTwith parents re-
porting lower functional status across almost all domains. For the
physical and psychosocial, and school scores are lower than healthy
child reference norms for parental ratings indicating concerns in
these domains. However by the 6 and 12 month mark after
HSCT, children are rating their QOL comparable to healthy peer
scores. Of note, parents experienced markedly less ‘‘worry’’ over
the first year (about treatment, side effects, social and interpersonal
relations, and child’s future), while children reported increasing
‘worry’ over the first year.Wewill further explore the role of etiology
for transplant and age of child and its impact on these findings; stud-
ies are needed to explore discordant parental and child perceptions of
QOL to improve outcomes for pediatric HSCT recipients.225
PHASE ANGLE FROM BIA IN PATIENTS WITH FANCONI ANEMIA UNDER-
GOING HEMATOPOIETIC STEM CELL TRANSPLANTATION
Farias, C.L.A.2, Campos, D.J.1, Bonfim, C.M.S.1, Vilela, R.M.3 1Uni-
versidade Federal do Parana, Curitiba, Parana, Brazil; 2Universidade
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Parana, Curitiba, Parana, Brazil
Patients with Fanconi Anemia (FA) often have compromised nu-
tritional status, especially low birth weight and short stature. Once
the Hematopoietic Stem Cell Transplantation (HSCT) causes loss
of appetite and increased energy expenditure, nutritional status of
these patients may be further compromised. Knowing that the phase
angle (PA) has been considered a prognostic and nutritional status
indicator in several clinical situations, considering its use as an
body cell mass estimate value, the aim of this study was to evaluate
the PA in patients with FA undergoing HSCT and the association
between PA and nutritional parameters. The nutritional status of
24 patients and 25 controls, aged from 5 to 16 years old, was assessed
by bioelectric impedance analysis (BIA) and anthropometric mea-
surements before patients started conditioning for HSCT and 30
and 180 days after HSCT. The PA was calculated (reactance/resis-
tance) and expressed in degrees. Dietary intake was assessed by 24-
hour recall. Of the 24 patients studied, 11 (45.8%) were male, with
an average age 9.746 3.2 years and mean PA of 5.8 6 0.82. The pa-
tients had lower PA values than the control (5.86 0.16 versus 6.36
0.13, respectively, p 5 0.02). Was observed a decrease of 17.3% in
the value of AF 30 days after transplantation (p5 0.02). On the other
hand, there was no reduction in mean BMI and FFM after transplan-
tation (p.0.05). Lower values of AF were found in patients classified
as malnourished according to weight / age (p5 0.007) as well as pa-
tients with weight loss 180 days after transplantation (p 5 0.002).
The PAwas positively correlated with age (r5 0.660 p\0.001), pro-
tein intake (r5 0.663 p5 0.003), BMI (r5 0.762 p\0.001), Triceps
skinfold thickness (r 5 0.457 p 5 0.02), Arm muscle circunference
(r 5 0.754 p\0,001) and Fat free mass (r 5 0.694 p\0.001). The
present study demonstrated that PA can be used as an indicator of
nutritional status in children with AF undergoing HSCT.
